Trials / Completed
CompletedNCT01781117
Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia
Prognostic Value of the Urinary Nerve Growth Factor (NGF) in the Patients With Benign Prostatic Hyperplasia (BPH) Who Undergo Holmium Laser Enucleation of the Prostate (HoLEP)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 184 (actual)
- Sponsor
- KYU-SUNG LEE · Academic / Other
- Sex
- Male
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
Persistent detrusor overactivity (DO) after transurethral prostatectomy results in symptomatic failure in more than one third of the patients. Storage symptoms are major complaints in the early postoperative period after Holmium Laser Enucleation of the Prostate (HoLEP). Levels of the urinary nerve growth factor (NGF), produced by bladder urothelium and smooth muscle, are increased in the patients with overactive bladder (OAB), and decreased after the OAB symptoms were improved. Also, urinary NGF levels are increased in patients with benign prostatic obstruction (BPO), but the changes of the NGF levels after relief of the BPO by the medical or surgical treatment have not been fully investigated. If the elevated urinary NGF levels are reduced after successful surgical treatment of BPO, measurement of urinary NGF could be a useful objective tool to assess the therapeutic outcomes of the operation. The aims of this study are to measure the urinary NGF levels in patients with BPO and to compare the results between the patients with detrusor overactivity (DO) and without detrusor overactivity (Non-DO), average 2 weeks before Holmium Laser Enucleation of the Prostate (HoLEP) procedure. After HoLEP, urinary NGF levels are rechecked at the periods of postoperative 3 months and 6 months, and compare changes between the two groups.
Detailed description
* Investigators are going to enroll age-matched control group and measure the urinary NGF levels as a baseline value (30 males). * Investigators are going to enroll BPO patients group (DO group 50 and Non-DO group 50 patients). * Administration of the anti-cholinergic agents was reported to decrease urinary NGF levels. Investigators are going to try to avoid the effect of anti-muscarinic drugs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Holmium Laser Enucleation of the Prostate (HoLEP) | Enucleation of the enlarged nodule of prostate and morcellation of the resected tissue. |
| DEVICE | Holmium laser enucleation system and morcellator | Holmium laser enucleation and morcellation |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2016-11-01
- Completion
- 2017-01-01
- First posted
- 2013-01-31
- Last updated
- 2019-12-02
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01781117. Inclusion in this directory is not an endorsement.